血液系统恶性肿瘤患者ICU治疗两周内预后确定性提升有限:限时试验分析
荷兰两家学术医疗中心的回顾性队列研究,纳入555例次活动性血液系统恶性肿瘤ICU入住,分别用入住第1、7、14天数据建立1年生存预测模型,AUC分别为0.71、0.67、0.66。个体层面,第1至7天仅2%患者熵值有意义的下降(熵降>0.25),另有12%因死亡而确定性增加;第7至14天分别为14%和18%。第1天存活者中,初始预后「不确定」者2%、「差」者10%在第7天转为更有利类别;第7天仍存活于ICU者中,相应比例为31%和16%。外部验证结果相当。结论:2周内预后确定性提升有限,模型整体表现中等。
要点
- 555例次血液系统恶性肿瘤ICU入住,第1、7、14天1年生存预测模型AUC分别为0.71、0.67、0.66,判别力中等。
- 第1至7天,仅2%患者预后确定性有意义增加(熵降>0.25),另有12%因死亡而确定性增加。
- 第7至14天,14%患者确定性有意义增加,另有18%因死亡而确定性增加。
- 第1天存活且初始预后「不确定」者中2%、「差」者中10%在第7天转为更有利类别。
- 第7天仍存活于ICU者中,初始「不确定」者31%、「差」者16%在第14天转为更有利类别。
适用人群与场景
- 活动性血液系统恶性肿瘤并入住ICU的患者。
- 荷兰两家学术医疗中心,并在一家美国三级医疗中心MIMIC-IV数据库进行外部验证。
研究设计与关键结果
- 回顾性队列研究,纳入555例次活动性血液系统恶性肿瘤ICU入住,用第1、7、14天数据分别建立1年生存预测模型,AUC分别为0.71、0.67和0.66。
- 第1至7天,2%患者熵值下降>0.25(预后确定性有意义增加),另有12%因死亡而确定性增加;第7至14天分别为14%和18%。
- 第1天存活者中,初始预后「不确定」者2%、「差」者10%在第7天转为更有利类别;第7天仍存活于ICU者中,相应比例为31%和16%。
- 外部验证队列结果与主要队列相当。
证据类型、等级与局限
- 证据类型:回顾性队列研究,外部验证。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,尽管使用丰富ICU数据集和不同先进建模策略,模型整体表现中等,提示该人群预后很大程度上由疾病相关和患者特异因素驱动,而非ICU病程。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: We aimed to examine how the predicted 1-year survival and its prognostic certainty evolve during the first two weeks of ICU admission.
DESIGN: Retrospective cohort study.
SETTING: Two academic medical centers in The Netherlands. External validation in the Medical Information Mart for Intensive Care-IV database from a tertiary medical center in the United States.
PATIENTS: Patients with active hematologic malignancies admitted to the ICU.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Separate prediction models for 1-year survival were developed using data available at day 1, 7, and 14 after ICU admission for 555, 181, and 94 ICU admissions resulting in an area under the receiver operating characteristics curves of 0.71, 0.67, and 0.66, respectively. At the individual patient level, prognostic certainty quantified by entropy increased meaningfully (entropy decrease > 0.25) in 2% of patients between day 1 and day 7 (in an additional 12% certainty increased because of death) and in 14% of patients between day 7 and day 14 (in an additional 18% because of death). Among patients alive on day 1, 2% of patients with an "uncertain" and 10% with a "poor" initial prognosis had shifted to a more favorable category by day 7. Of the patients alive and still in the ICU on day 7, 31% of patients with an "uncertain" and 16% with a "poor" prognosis had shifted to a more favorable category by day 14. Results in the external validation cohort were comparable.
CONCLUSIONS: In patients with hematologic malignancies admitted to the ICU, prognostic certainty about long-term survival increased little during in the first 2 weeks of ICU admission, aside from increases in prognostic certainty due to early mortality. Despite the use of rich ICU datasets and different state-of-the-art modeling strategies, overall model performance was modest, suggesting that prognosis in this population is largely driven by disease-related and patient-specific factors beyond the ICU course.
参考来源
- Otten M, van der Woude B, van Kempen BJH, et al. Minimal Gain in Prognostic Certainty for Patients With Hematologic Malignancies Over 2 Weeks of Intensive Care: An Analysis to Inform Time-Limited Trials. Crit Care Med. 2026. PMID: 41498592. doi:10.1097/CCM.0000000000007006
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。